Resurfacing an August move: Marico Q1 FY26 revenue rose 23% as India business grew 27%; profit up 8%

Marico had reported Q1 FY26 revenue from operations of Rs 3,259 crore, up 23.3% year on year, with India revenue growing 27.2% to Rs 2,495 crore. Consolidated net profit rose 8.2% to Rs 513 crore. The company also lifted its stake in Plix maker Satiya Nutraceuticals to 60% on a fully diluted basis.

— FiledTue, 22 Sept, 2026, 06:19 IST·First seen Tue, 22 Sept, 2026, 06:18 IST·Source Financial Express · BrandWagon

What happened

Marico reported strong Q1 FY26 growth, led by a 27.17% increase in India revenue and 8.2% profit growth. It expects sustained volume and revenue momentum

Key facts

  • Q1 FY26 consolidated net profit rose 8.2% YoY to Rs 513 crore from Rs 474 crore
  • Revenue from operations rose 23.31% to Rs 3,259 crore from Rs 2,643 crore
  • Total income was Rs 3,315 crore, including Rs 56 crore other income
  • Total expenses rose to Rs 2,659 crore from Rs 2,075 crore
  • India revenue grew 27.17% to Rs 2,495 crore from Rs 1,962 crore
  • International revenue grew 12.91% to Rs 764 crore from Rs 681 crore
  • India segment PBT was Rs 469 crore
  • International segment PBT was Rs 213 crore
  • Marico increased its stake in Satiya Nutraceuticals to 60% on a fully diluted basis

Why this matters

Increasing the Plix stake to 60% deepens Marico’s exposure to fast-growing wellness and nutrition, reinforcing its portfolio shift beyond core FMCG.

What to watch

  • Sequential India volume growth versus price-led growth in the next quarterly update.
  • Gross-margin and EBITDA-margin movement, particularly relative to revenue growth.
  • Copra, edible oil, crude-linked packaging and freight cost trends.
  • Advertising and sales-promotion expense growth as a percentage of revenue.
  • Plix revenue growth, offline retail expansion, new product cadence and evidence of post-acquisition profitability.
  • Market-share trends in coconut oil, value-added hair oils, foods and wellness categories.
  • Management commentary on pricing actions, rural demand, urban discretionary consumption and FY26 margin guidance.
  • Increase distribution and marketing support behind faster-growing India categories, especially foods, premium personal care, health and nutrition.
  • Integrate Plix/Satiya Nutraceuticals more closely through retail distribution expansion, product launches, supply-chain leverage and omnichannel cross-selling.
  • Use calibrated price increases, grammage adjustments and premium SKU mix to protect margins if copra, edible oil or packaging costs remain elevated.
  • Maintain elevated advertising and promotional spending to defend share against FMCG incumbents and digital-native wellness brands.
  • Seek international growth diversification while keeping India as the primary growth and investment engine.